Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
China Isotope & Radiation Corp. ( (HK:1763) ) has shared an update.
China Isotope & Radiation Corporation announced that shareholders at its first extraordinary general meeting of 2026 approved a series of renewed framework agreements governing products and services supply, products and services purchase, engineering construction services, and financial services, all with proposed annual caps. Despite CNNC and its associates abstaining from voting due to material interests in these connected transactions, all four ordinary resolutions were passed by poll—three with unanimous support and the financial services framework with more than 92% approval—thereby providing formal shareholder backing for the continuation of key related-party arrangements that underpin the company’s ongoing operations and financing structure.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$26.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
More about China Isotope & Radiation Corp.
China Isotope & Radiation Corporation is a Hong Kong-listed joint stock company incorporated in the People’s Republic of China, focused on isotope and radiation-related businesses. Its share capital is divided into H shares listed in Hong Kong and domestic shares, with China National Nuclear Corporation (CNNC) and its associates holding a controlling stake of about 73.83% of the company’s issued share capital.
Average Trading Volume: 365,574
Technical Sentiment Signal: Buy
Current Market Cap: HK$7.26B
For detailed information about 1763 stock, go to TipRanks’ Stock Analysis page.